
Show Notes
In this episode of Psychiatry Boot Camp, Dr. Mark Mullen speaks with Dr. Owen Muir, psychiatrist, entrepreneur, and Chief Medical Officer of Radial Health, about the growing role of transcranial magnetic stimulation (TMS) in psychiatric treatment.The discussion explores how TMS works as a form of noninvasive neuromodulation, using focused magnetic fields to influence neural circuits implicated in depression and other psychiatric conditions. Dr. Muir reviews the evidence supporting TMS for treatment-resistant depression, explains the FDA clearance pathway for neuromodulation devices, and discusses how stimulation parameters, coil positioning, and treatment protocols affect clinical outcomes.The conversation also addresses the broader implications of neuromodulation in psychiatry, including emerging indications, technological innovation, and how clinicians can integrate TMS into modern psychiatric practice. This episode provides a practical and conceptual overview of one of the fastest-growing treatment modalities in mental health care.
Takeaways:
TMS is a noninvasive neuromodulation technique that uses magnetic fields to induce electrical activity in targeted cortical regions.The primary FDA-cleared indication is treatment-resistant major depressive disorder, though research continues for other conditions including OCD and PTSD.Treatment protocols depend on stimulation parameters, including frequency, location (often the dorsolateral prefrontal cortex), and session scheduling.The FDA device clearance process differs from pharmaceutical approval, relying heavily on device equivalence and clinical safety data.Neuromodulation represents a growing frontier in psychiatry, complementing pharmacotherapy and psychotherapy in the treatment of complex mood disorders.
SUPPORT OUR PARTNERS:
SimplePractice.com/bootcamp (Now with AI documentation! Exclusive 7 day free trial and 50% off four months)
Beat the Boards Boot camp listeners now get FREE access to over 4400 exam-style questions)
Cozy Earth: Start the New Year off right and give your home the luxury it deserves, and make home the best part of life. Head to http://www.cozyearth.com and use my code BOOTCAMP for up to 20% off. And if you get a Post-Purchase Survey, be sure to mention you heard about Cozy Earth right here!
Learn more and get transcripts for EVERY episode at https://www.psychiatrybootcamp.com/
For Sales Inquiries & Ad Rates, Please Contact:[email protected]
Connect with HumanContent on Socials: @humancontentpods
Produced by: Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Psychiatry Boot Camp
In this episode of Psychiatry Boot Camp, Dr. Mark Mullen continues his conversation with Dr. Jacob Appel, covering two intersecting frontiers. The replacement of human physicians by AI "replicants" and the emerging use of AI as a surrogate decision-maker, or "robo-proxy," for patients who lack decisional capacity. Dr. Appel argues that while AI will outperform human physicians in probabilistic, pattern-recognition tasks, it is structurally incapable of providing the authentic empathy, shared vulnerability, common sense, and irrational human trust that constitute the actual substance of healing and that deploying replicant physicians at scale will produce a deeply inequitable two-tiered healthcare system where wealthy patients see humans and less wealthy patients see machines.
In this episode of Psychiatry Bootcamp, Dr. Mark Mullen welcomes Dr. Jacob Appel, psychiatrist, attorney, bioethicist, polymath, and emergency psychiatrist, for a rigorous and clinically grounded critique of the Applebaum-Grisso "Four Abilities Model" of decisional capacity assessment. Dr. Appel traces the model's origins in the 1980s as a patient-empowerment tool, examines how its statutory adoption across more than half of US states has calcified it beyond its original intent, and describes in detail the categories of patients for whom the model systematically fails.
In this episode of Psychiatry Boot Camp recorded live at Saint Louis University, Dr. Mark Mullen is joined by Dr. Kristin Mueller, an emergency medicine physician and physician-researcher at Washington University in St. Louis, for a discussion on firearm violence as a public health crisis. Dr. Mueller, who works closely with the Life Outside of Violence hospital-based violence intervention program, walks through the clinical fundamentals of lethal means counseling, including a live mock counseling session demonstrating how to approach a patient in mental health crisis with access to firearms. The conversation covers practical, evidence-informed strategies for secure storage counseling, verbal de-escalation, and navigating patient resistance without leading with statistics alone.
Dr. Mark Mullen welcomes Dr. Allison Hadley, a psychiatrist and medical director of the psychiatric emergency service at Oregon Health & Science University, for a discussion on motivational interviewing in high-acuity psychiatric settings. Dr. Hadley introduces a novel teaching framework that draws on Tina Fey's rules of improv from her memoir Bossy Pants, mapping core improv principles, including "yes, and," making statements rather than only asking questions, and treating perceived mistakes as opportunities, onto the foundational techniques of motivational interviewing. The conversation covers the OARS mnemonic (open-ended questions, affirmations, reflections, and summaries), the relationship between motivational interviewing and trauma-informed care, and practical strategies for identifying and reinforcing patient change talk.
Dr. Mark Mullen welcomes Dr. Christine Crawford, Chief Medical Officer at the National Alliance on Mental Illness (NAMI) and author of You Are Not Alone: For Parents and Caregivers, alongside Steve Hoffmann, Senior Vice President and Chief Preclinical Officer at the Foundation for the National Institutes of Health (FNIH). Dr. Crawford discusses NAMI's mission and its 650 chapters nationwide, the concept of the "distress radius" as a framework for identifying when a child's behavioral changes warrant professional evaluation, and practical strategies for engaging skeptical patients and families through primary care. She also highlights dialectical behavioral therapy (DBT) as a broadly applicable clinical tool and underscores the importance of evidence-based education for patients and caregivers navigating the mental health system. The conversation then shifts to Steve Hoffmann's work at the FNIH, including the newly launching Multimodal Assessment and Phenotyping in Depression (MAPD) study, a longitudinal, multi-site initiative designed to identify biological, clinical, and digital biomarkers associated with depression subtypes. Hoffmann outlines the study's design, including neuroimaging, genetic testing, digital wearables, and patient-reported outcomes, with the goal of moving depression treatment away from a trial-and-error model toward a precision medicine approach. Dr. Crawford and Hoffmann both emphasize the importance of including patient voices in research design, drawing parallels to the foundational impact of the Alzheimer's Disease Neuroimaging Initiative (ADNI) on that field.